Shots:

• JAMP Pharma has received the marketing authorization from Health Canada for a high-concentration biosimilar to Humira (adalimumab)
• Upon the exclusive commercialization agreement with JAMP Pharma, AVT02 (100 mg/mL) will be marketed as Simlandi in Canada & will provide Canadians access to a biosimilar that is also used across both EU and the US
• Simlandi is a high-concentration, citrate-free biosimilar to Humira & is used to treat inflammatory conditions. Additionally, JAMP Pharma’s commercial infrastructure and expertise will allow Canadian patients to benefit from safe and effective biosimilars along with JAMP Care patient support program

Ref: Alvotech | Image: Businesswire